Oxford Biomedica PLC Grant of options (5311U)

TIDMOXB

RNS Number : 5311U

Oxford Biomedica PLC

24 November 2023

Grant of options

London, UK - 24 November 2023: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, announces that on 23 November 2023 nil-cost share options over Ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

2023 LTIP Awards

 
 Name of individual         Title            Number of      Total shares    Percentage of 
                                           shares subject    over which     current issued 
                                            to the 2023      options now    share capital 
                                             LTIP award         held         under option 
                       Chief Operating 
 Thierry Cournez            Officer           66,437           66,437          0.069% 
                      -----------------  ----------------  -------------  ---------------- 
 

The LTIP awards are subject to performance conditions. As set out in the 2022 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2023, 2024 and 2025) and strategic milestones (20% of the award).

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                           Thierry Cournez 
     -----------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                Chief Operating Officer 
     -----------------------------  ----------------------------------------- 
 b)   Initial notification/          Initial Notification 
       amendment 
     -----------------------------  ----------------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                           Oxford Biomedica plc 
     -----------------------------  ----------------------------------------- 
 b)   LEI code                       213800S1GVQNXQ15K851 
     -----------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of                 Ordinary Shares of 50 pence each 
       the financial 
       instrument                     ISIN: GB00BDFBVT43 
 
       Identification 
       code 
     -----------------------------  ----------------------------------------- 
 b)   Nature of the                  Grant of awards over Ordinary Shares 
       transaction                    under the Company's Long Term Incentive 
                                      Plan. No consideration was paid for 
                                      the grant of awards. 
     -----------------------------  ----------------------------------------- 
 c)   Price(s) and volumes(s)        2023 LTIP Award 
                                       Price    Volume 
                                       Nil      66,437 
                                               ------- 
     -----------------------------  ----------------------------------------- 
 d)        Aggregated information 
             *    Aggregate volume     Awards granted over 66,437 shares in 
                                       total 
 
 
             *    Price                N/A 
     -----------------------------  ----------------------------------------- 
 e)   Date of the transaction        2023-11-23 
     -----------------------------  ----------------------------------------- 
 f)   Place of the transaction       Outside of trading venue 
     -----------------------------  ----------------------------------------- 
 

-Ends-

 
 For further information, please 
  contact: 
 
   Oxford Biomedica plc:                 Tel: [phone] 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com , and follow us on LinkedIn and YouTube .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDGBDBGUDDGXX

(END) Dow Jones Newswires

November 24, 2023 02:00 ET (07:00 GMT)